vs
Side-by-side financial comparison of Viridian Therapeutics, Inc.\DE (VRDN) and WEALTHFRONT CORP (WLTH). Click either name above to swap in a different company.
WEALTHFRONT CORP is the larger business by last-quarter revenue ($93.2M vs $70.6M, roughly 1.3× Viridian Therapeutics, Inc.\DE). WEALTHFRONT CORP runs the higher net margin — 33.1% vs -49.0%, a 82.2% gap on every dollar of revenue.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
Wealthfront Corporation is a financial services company based in Palo Alto, California, founded by Andy Rachleff and Dan Carroll in 2008. As of 2025, Wealthfront had $88 billion AUM across more than 1.3 million clients.
VRDN vs WLTH — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $70.6M | $93.2M |
| Net Profit | $-34.6M | $30.9M |
| Gross Margin | — | 89.1% |
| Operating Margin | -56.7% | 37.3% |
| Net Margin | -49.0% | 33.1% |
| Revenue YoY | 81958.1% | — |
| Net Profit YoY | 54.9% | — |
| EPS (diluted) | — | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $93.2M | ||
| Q3 25 | $70.6M | — |
| Q4 25 | — | $30.9M | ||
| Q3 25 | $-34.6M | — |
| Q4 25 | — | 89.1% | ||
| Q3 25 | — | — |
| Q4 25 | — | 37.3% | ||
| Q3 25 | -56.7% | — |
| Q4 25 | — | 33.1% | ||
| Q3 25 | -49.0% | — |
| Q4 25 | — | $0.21 | ||
| Q3 25 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $490.9M | $266.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $503.0M | $125.4M |
| Total Assets | $577.1M | $810.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $266.2M | ||
| Q3 25 | $490.9M | — |
| Q4 25 | — | $125.4M | ||
| Q3 25 | $503.0M | — |
| Q4 25 | — | $810.6M | ||
| Q3 25 | $577.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-84.6M | — |
| Free Cash FlowOCF − Capex | $-84.7M | — |
| FCF MarginFCF / Revenue | -120.1% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $-84.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | $-84.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | -120.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.2% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
